Group 1 - BeOne Medicines AG (NASDAQ:ONC) is recognized as a high growth international stock, with a Buy rating and a price target of $414 from Bernstein and $394 from Barclays [1][2][4] - The company received the first-in-world approval for its drug Sonrotoclax in China, aimed at treating relapsed/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) [2][4] - The MCL study showed a 52.4% overall response rate (ORR) and the CLL/SLL study demonstrated a 77% ORR, indicating strong efficacy of Sonrotoclax [4] Group 2 - Management emphasizes that the approval in China is part of a global rollout strategy for BeOne Medicines AG [4] - Bernstein's Rebecca Liang believes the company's pipeline is undervalued and highlights Sonrotoclax as having potential best-in-class status [4] - BeOne Medicines AG is a global oncology company focused on innovative cancer treatments for hematology and solid tumors [4]
Bernstein Remains a Buy on BeOne Medicines AG (ONC)